BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 27313781)

  • 21. Highly Concordant Key Genetic Alterations in Primary Tumors and Matched Distant Metastases in Differentiated Thyroid Cancer.
    Sohn SY; Park WY; Shin HT; Bae JS; Ki CS; Oh YL; Kim SW; Chung JH
    Thyroid; 2016 May; 26(5):672-82. PubMed ID: 26971368
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Identification of h-TERT Promoter Mutations in Germline DNA from North Indian Lung Carcinoma Patients.
    Prasad R; Panchal S; Rani I; Kishan J; Parashar G
    Indian J Clin Biochem; 2023 Jan; 38(1):120-127. PubMed ID: 36684496
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Telomerase reverse transcriptase promoter mutations in cancers derived from multiple organ sites among middle eastern population.
    Siraj AK; Bu R; Iqbal K; Parvathareddy SK; Siraj N; Siraj S; Diaz MRF; Rala DR; Benito AD; Sabido MA; Al-Rasheed M; Al-Obaisi KAS; Al-Haqawi W; Victoria IG; Al Balawy W; Abedalthagafi M; Wakil SM; Ajarim D; Mohammed S; Alhussain T; Tulbah A; Al-Badawi IA; Al-Dayel F; Al-Kuraya KS
    Genomics; 2020 Mar; 112(2):1746-1753. PubMed ID: 31669704
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prognostic quality of activating TERT promoter mutations in glioblastoma: interaction with the rs2853669 polymorphism and patient age at diagnosis.
    Spiegl-Kreinecker S; Lötsch D; Ghanim B; Pirker C; Mohr T; Laaber M; Weis S; Olschowski A; Webersinke G; Pichler J; Berger W
    Neuro Oncol; 2015 Sep; 17(9):1231-40. PubMed ID: 25681309
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Recurrent TERT promoter mutations in urothelial carcinoma and potential clinical applications.
    Kurtis B; Zhuge J; Ojaimi C; Ye F; Cai D; Zhang D; Fallon JT; Zhong M
    Ann Diagn Pathol; 2016 Apr; 21():7-11. PubMed ID: 27040924
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Molecular profiling, including TERT promoter mutations, of acral lentiginous melanomas.
    Vazquez Vde L; Vicente AL; Carloni A; Berardinelli G; Soares P; Scapulatempo C; Martinho O; Reis RM
    Melanoma Res; 2016 Apr; 26(2):93-9. PubMed ID: 26709572
    [TBL] [Abstract][Full Text] [Related]  

  • 27. TERT promoter hot spot mutations are frequent in Indian cervical and oral squamous cell carcinomas.
    Vinothkumar V; Arunkumar G; Revathidevi S; Arun K; Manikandan M; Rao AK; Rajkumar KS; Ajay C; Rajaraman R; Ramani R; Murugan AK; Munirajan AK
    Tumour Biol; 2016 Jun; 37(6):7907-13. PubMed ID: 26700669
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Arms-qPCR Improves Detection Sensitivity of Earlier Diagnosis of Papillary Thyroid Cancers With Worse Prognosis Determined by Coexisting BRAF V600E and Tert Promoter Mutations.
    Yu PC; Tan LC; Zhu XL; Shi X; Chernikov R; Semenov A; Zhang L; Ma B; Wang Y; Zhou XY; Ji QH; Wei WJ; Wang YL
    Endocr Pract; 2021 Jul; 27(7):698-705. PubMed ID: 33515759
    [TBL] [Abstract][Full Text] [Related]  

  • 29. TERT promoter mutations in thyroid cancer.
    Liu R; Xing M
    Endocr Relat Cancer; 2016 Mar; 23(3):R143-55. PubMed ID: 26733501
    [TBL] [Abstract][Full Text] [Related]  

  • 30. TERT promoter mutations are associated with distant metastases in papillary thyroid carcinoma.
    Gandolfi G; Ragazzi M; Frasoldati A; Piana S; Ciarrocchi A; Sancisi V
    Eur J Endocrinol; 2015 Apr; 172(4):403-13. PubMed ID: 25583906
    [TBL] [Abstract][Full Text] [Related]  

  • 31. TERT promoter mutations in clear cell renal cell carcinoma.
    Hosen I; Rachakonda PS; Heidenreich B; Sitaram RT; Ljungberg B; Roos G; Hemminki K; Kumar R
    Int J Cancer; 2015 May; 136(10):2448-52. PubMed ID: 25331263
    [TBL] [Abstract][Full Text] [Related]  

  • 32. High prevalence of TERT promoter mutations in micropapillary urothelial carcinoma.
    Nguyen D; Taheri D; Springer S; Cowan M; Guner G; Mendoza Rodriguez MA; Wang Y; Kinde I; VandenBussche CJ; Olson MT; Ricardo BF; Cunha I; Fujita K; Ertoy D; Kinzler KW; Bivalacqua TJ; Papadopoulos N; Vogelstein B; Netto GJ
    Virchows Arch; 2016 Oct; 469(4):427-34. PubMed ID: 27520411
    [TBL] [Abstract][Full Text] [Related]  

  • 33. BRAF and TERT promoter mutations in the aggressiveness of papillary thyroid carcinoma: a study of 653 patients.
    Jin L; Chen E; Dong S; Cai Y; Zhang X; Zhou Y; Zeng R; Yang F; Pan C; Liu Y; Wu W; Xing M; Zhang X; Wang O
    Oncotarget; 2016 Apr; 7(14):18346-55. PubMed ID: 26943032
    [TBL] [Abstract][Full Text] [Related]  

  • 34.
    Batista R; Lima L; Vinagre J; Pinto V; Lyra J; Máximo V; Santos L; Soares P
    Int J Mol Sci; 2020 Jan; 21(3):. PubMed ID: 32023888
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Telomerase reverse transcriptase (TERT) promoter mutations are rare in urachal cancer.
    Thiem S; Herold T; Krafft U; Bremmer F; Tolkach Y; Szász AM; Kriegsmann J; Gaisa NT; Niedworok C; Szarvas T; Reis H
    Pathol Int; 2017 Dec; 67(12):597-601. PubMed ID: 29047227
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Highly prevalent BRAF V600E and low-frequency TERT promoter mutations underlie papillary thyroid carcinoma in Koreans.
    Kim SY; Kim T; Kim K; Bae JS; Kim JS; Jung CK
    J Pathol Transl Med; 2020 Jul; 54(4):310-317. PubMed ID: 32527075
    [TBL] [Abstract][Full Text] [Related]  

  • 37. TERT promoter mutations are a major indicator of recurrence and death due to papillary thyroid carcinomas.
    Bullock M; Ren Y; O'Neill C; Gill A; Aniss A; Sywak M; Sidhu S; Delbridge L; Learoyd D; de Vathaire F; Robinson BG; Clifton-Bligh RJ
    Clin Endocrinol (Oxf); 2016 Aug; 85(2):283-90. PubMed ID: 26667986
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Absence of TERT promoter mutations in colorectal precursor lesions and cancer.
    Cruvinel-Carloni A; Yamane L; Scapulatempo-Neto C; Guimarães D; Reis RM
    Genet Mol Biol; 2018; 41(1):82-84. PubMed ID: 29473934
    [TBL] [Abstract][Full Text] [Related]  

  • 39. TERT promoter hotspot mutations and gene amplification in metaplastic breast cancer.
    da Silva EM; Selenica P; Vahdatinia M; Pareja F; Da Cruz Paula A; Ferrando L; Gazzo AM; Dopeso H; Ross DS; Bakhteri A; Riaz N; Chandarlapaty S; Razavi P; Norton L; Wen HY; Brogi E; Weigelt B; Zhang H; Reis-Filho JS
    NPJ Breast Cancer; 2021 Apr; 7(1):43. PubMed ID: 33863915
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Telomerase reverse transcriptase gene promoter mutations help discern the origin of urogenital tumors: a genomic and molecular study.
    Wu S; Huang P; Li C; Huang Y; Li X; Wang Y; Chen C; Lv Z; Tang A; Sun X; Lu J; Li W; Zhou J; Gui Y; Zhou F; Wang D; Cai Z
    Eur Urol; 2014 Feb; 65(2):274-7. PubMed ID: 24215939
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.